Abstract
Despite the efficacy of tamoxifen in preventing disease relapse, a large portion of breast cancer patients show intrinsic or acquired resistance to tamoxifen, leading to treatment failure and unfavorable clinical outcome. MYB proto-oncogene like 2 (MYBL2) is a transcription factor implicated in the initiation and progression of various human cancers. However, its role in tamoxifen resistance in breast cancer remained largely unknown. In the present study, by analyzing public transcriptome dataset, we found that MYBL2 is overexpressed in breast cancer and is associated with the poor prognosis of breast cancer patients. By establishing tamoxifen-resistant breast cancer cell lines, we also provided evidence that MYBL2 overexpression contributes to tamoxifen resistance by up-regulating its downstream transcriptional effectors involved in cell proliferation (PLK1, PRC1), survival (BIRC5) and metastasis (HMMR). In contrast, inhibiting those genes via MYBL2 depletion suppresses cancer progression, restores tamoxifen and eventually reduces the risk of disease recurrence. All these findings revealed a critical role of MYBL2 in promoting tamoxifen resistance and exacerbating the progression of breast cancer, which may serve as a novel therapeutic target to overcome drug resistance and improve the prognosis of breast cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data that supports the findings of this study are included in this published article.
References
Cervellera M et al (2000) Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. J Biol Chem 275:21055–21060. doi:https://doi.org/10.1074/jbc.M002055200
de Medina P et al (2004) Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 308:1165–1173. doi:https://doi.org/10.1124/jpet.103.060426
de Medina P, Silvente-Poirot S, Poirot M (2009) Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 5:1066–1067. https://doi.org/10.4161/auto.5.7.9820
de Medina P, Paillasse MR, Segala G, Poirot M, Silvente-Poirot S (2010) Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc Natl Acad Sci U S A 107:13520–13525. doi:https://doi.org/10.1073/pnas.1002922107
de Medina P et al (2011) Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chem Phys Lipids 164:432–437. doi:https://doi.org/10.1016/j.chemphyslip.2011.05.005
Grassilli E, Salomoni P, Perrotti D, Franceschi C, Calabretta B (1999) Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. Cancer Res 59:2451–2456
Inoue K, Fry EA (2016) Novel molecular markers for breast cancer. Biomark Cancer 8:25–42. https://doi.org/10.4137/BIC.S38394
Ivshina AV et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of. breast cancer Cancer Res 66:10292–10301. doi:https://doi.org/10.1158/0008-5472.CAN-05-4414
Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. doi:https://doi.org/10.1038/nrd1031
Kohno K et al (2005) Transcription factors and drug resistance. Eur J Cancer 41:2577–2586. doi:https://doi.org/10.1016/j.ejca.2005.08.007
Levenson VV, Davidovich IA, Roninson IB (2000) Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 60:5027–5030
Li J, Lu M, Jin J, Lu X, Xu T, Jin S (2018) miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Cell Physiol Biochem 50:136–149. doi:https://doi.org/10.1159/000493964
Liang HB et al (2017) MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. Cell Physiol Biochem 41:2117–2131. doi:https://doi.org/10.1159/000475454
Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TG (2017) MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis 8:e2895. doi:https://doi.org/10.1038/cddis.2017.244
Oki S et al (2018) ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data EMBO Rep 19 doi:https://doi.org/10.15252/embr.201846255
Osterloh L et al (2007) The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosis. EMBO J 26:144–157. doi:https://doi.org/10.1038/sj.emboj.7601478
Payre B et al (2008) Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Mol Cancer Ther 7:3707–3718. doi:https://doi.org/10.1158/1535-7163.MCT-08-0507
Peters D, Freund J, Ochs RL (2005) Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 4:1605–1616. doi:https://doi.org/10.1158/1535-7163.MCT-04-0311
Qin H, Li Y, Zhang H, Wang F, He H, Bai X, Li S (2019) Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma. Onco Targets Ther 12:1917–1927. doi:https://doi.org/10.2147/OTT.S190145
Ring A, Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643–658. doi:https://doi.org/10.1677/erc.1.00776
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP (2011) Integrative genomics viewer Nat Biotechnol 29:24–26. doi:https://doi.org/10.1038/nbt.1754
Sadasivam S, Duan S, DeCaprio JA (2012) The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 26:474–489. doi:https://doi.org/10.1101/gad.181933.111
Sadasivam S, DeCaprio JA (2013) The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer 13:585–595. doi:https://doi.org/10.1038/nrc3556
Sala A et al (1997) Activation of human B-MYB by cyclins. Proc Natl Acad Sci U S A 94:532–536. doi:https://doi.org/10.1073/pnas.94.2.532
Santilli G, Schwab R, Watson R, Ebert C, Aronow BJ, Sala A (2005) Temperature-dependent modification and activation of B-MYB: implications for cell survival. J Biol Chem 280:15628–15634. doi:https://doi.org/10.1074/jbc.M411747200
Schubert S, Horstmann S, Bartusel T, Klempnauer KH (2004) The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1. Oncogene 23:1392–1404. doi:https://doi.org/10.1038/sj.onc.1207255
Seong HA, Manoharan R, Ha H (2011) B-MYB positively regulates serine-threonine kinase receptor-associated protein (STRAP) activity through direct interaction. J Biol Chem 286:7439–7456. doi:https://doi.org/10.1074/jbc.M110.184382
Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550. doi:https://doi.org/10.1073/pnas.0506580102
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45:W98–W102. doi:https://doi.org/10.1093/nar/gkx247
Tao D, Pan Y, Lu H, Zheng S, Lin H, Fang H, Cao F (2014) B-myb is a gene implicated in cell cycle and proliferation of breast cancer. Int J Clin Exp Pathol 7:5819–5827
Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin H, Cao F (2015) B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell. Med Oncol 32:412. doi:https://doi.org/10.1007/s12032-014-0412-y
Tarasov KV et al (2008a) B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS One 3:e2478. doi:https://doi.org/10.1371/journal.pone.0002478
Tarasov KV et al (2008b) Linkage of pluripotent stem cell-associated transcripts to regulatory gene networks. Cells Tissues Organs 188:31–45. doi:https://doi.org/10.1159/000118787
Wang J, Li H, Liang Z (2019) circ-MYBL2 serves as a sponge for miR-361-3p promoting cervical cancer cells proliferation and invasion. Onco Targets Ther 12:9957–9964. https://doi.org/10.2147/OTT.S218976
Ye H, Li L, Guo H, Yin Y (2012) MYBL2 is a substrate of GSK3-like kinase BIN2 and acts as a corepressor of BES1 in brassinosteroid signaling pathway in Arabidopsis. Proc Natl Acad Sci U S A 109:20142–20147. doi:https://doi.org/10.1073/pnas.1205232109
Yuan J, Zhang Y, Sheng Y, Fu X, Cheng H, Zhou R (2015) MYBL2 guides autophagy suppressor VDAC2 in the developing ovary to inhibit autophagy through a complex of VDAC2-BECN1-BCL2L1 in mammals Autophagy 11:1081–1098 doi:https://doi.org/10.1080/15548627.2015.1040970
Zhan M et al (2012) The B-MYB transcriptional network guides cell cycle progression and fate decisions to sustain self-renewal and the identity of pluripotent stem cells. PLoS One 7:e42350. doi:https://doi.org/10.1371/journal.pone.0042350
Zhang X, Lv QL, Huang YT, Zhang LH, Zhou HH (2017) Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res 36:105. doi:https://doi.org/10.1186/s13046-017-0573-6
Zhu W, Giangrande PH, Nevins JR (2004) E2Fs link the control of G1/S and G2/M transcription. EMBO J 23:4615–4626. doi:https://doi.org/10.1038/sj.emboj.7600459
Zhu Y et al (2018) Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nat Commun 9:1595. doi:https://doi.org/10.1038/s41467-018-03951-0
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
All authors have given consent for submission and publication of the manuscript.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Li, X., Zhang, X., Wu, CC. et al. The role of MYB proto-oncogene like 2 in tamoxifen resistance in breast cancer. J Mol Histol 52, 21–30 (2021). https://doi.org/10.1007/s10735-020-09920-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-020-09920-6